During GLP-1associated weight loss, lean-mass changes are typically adaptive and preventable , not degenerative. GLP-1 Body Composition Changes: What Clinical Trials Show About Muscle Loss Clinical trials and body-composition sub-studies of semaglutide and tirzepatide consistently demonstrate: Fat mass accounts for most weight lost during treatment. Lean mass may decrease , particularly without resistance training or adequate protein intake. In many patients, the proportion of lean mass relative to total body weight is preserved or improved , because fat loss exceeds lean loss. Key clinical insight: GLP-1/GIP therapies improve overall body composition by preferentially reducing fat massnot by causing muscle breakdown. Lean mass refers to all the non-fat tissues in the bodyprimarily skeletal muscle , but also organs, bones, connective tissue, and body waterthat support metabolism, movement, and overall physical function

We believe in empowering our clients with knowledge, and our experienced healthcare professionals are dedicated to guiding you through these treatment options
"Ive been on both Wegovy and Zepbound and I've lost 80 pounds with minimal side effects
Indeed, in January 2025, the Surgeon General of the United States released a report raising awareness of the links between cancer and alcohol consumption 4